Anti-fibrotic medicament
US5993845A · kind A · utility
29Cited by
0References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 3, 1997 |
| Grant date | Nov 30, 1999 |
| Priority date | — |
| Expiry date | Sep 3, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P17/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of submicromolar concentrations of a histone deacetylase inhibitor, useful as anti-fibrotic agents. The compounds strongly inhibit three main features of myofibroblastic differentiation of cultured hepatic stellate cells and of skin fibroblasts: (1) synthesis of collagens type I and III, the predominant collagens in fibrosis of liver and other organs; (2) cellular proliferation; and (3) expression of smooth muscle .alpha.-actin, a marker for activated myofibroblasts. Preferred compounds include trichostatin A or a pharmaceutically acceptable salt thereof, and sodium butyrate.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.